GLP-1 medications and PCOS: what they can and can’t do.
Semaglutide, tirzepatide and related medicines have changed weight-management care, and people with PCOS are asking whether they’re right for them. Here’s a balanced look at the evidence, the trade-offs and the questions to bring to your prescriber.
GLP-1 receptor agonists mimic a gut hormone that increases insulin release after meals, slows stomach emptying and reduces appetite. Some (semaglutide as Wegovy, liraglutide as Saxenda) are approved for chronic weight management; others are approved for type 2 diabetes. Tirzepatide acts on GLP-1 and GIP receptors. None are approved specifically for PCOS, so in PCOS they’re prescribed for weight or metabolic indications.
What the research shows in PCOS
- Weight and BMI. A 2026 network meta-analysis of 16 randomised trials in Frontiers in Endocrinology found GLP-1 receptor agonists — especially combined with metformin — gave the largest reductions in weight and BMI compared with metformin or inositol alone. GLP-1 monotherapy alone showed a mean weight difference of about 5 kg. Effects on HOMA-IR were not significant and results were heterogeneous.
- Androgens. Another 2026 network meta-analysis of 29 trials in the Journal of Ovarian Research found metformin plus a GLP-1 receptor agonist produced the greatest reductions in total testosterone and free androgen index — at the cost of more gastrointestinal side effects. Certainty for most comparisons was moderate to very low.
- Cycles and fertility. Small studies suggest improved menstrual regularity with weight loss, but large trials with fertility outcomes are lacking.
The 2023 international guideline includes anti-obesity medications as an option for adults with PCOS and excess weight, in addition to lifestyle, with attention to cost, side effects and the need for contraception.
GLP-1s vs metformin
| Metformin | GLP-1 receptor agonists | |
|---|---|---|
| How it works | Reduces liver glucose output; improves insulin sensitivity | Appetite reduction, slower gastric emptying, glucose-dependent insulin release |
| Weight effect in PCOS | Modest | Substantially larger in trials |
| Guideline position | Recommended for metabolic outcomes in adults with BMI ≥25 | Option for adults with excess weight, alongside lifestyle |
| Common side effects | Diarrhoea, nausea (often reduced by extended-release forms) | Nausea, vomiting, constipation, reduced appetite |
| Cost/access | Inexpensive, generic | Often expensive; coverage varies |
| Pregnancy | Discuss with prescriber; sometimes continued under specialist care | Stop before conception (semaglutide: ≥2 months) |
Side effects and safety
- Gastrointestinal effects are the most common and usually ease with slow dose increases.
- Muscle loss. A 2026 meta-analysis found lean mass accounted for about 28% of the weight lost on GLP-1 receptor agonists and SGLT2 inhibitors. Prioritising protein and strength training helps preserve muscle.
- Rarer risks listed in prescribing information include pancreatitis, gallbladder disease and a boxed warning about thyroid C-cell tumours seen in rodents. Discuss your personal and family history with your prescriber.
- Stopping often leads to weight regain, so these are generally considered long-term therapies.
Pregnancy and contraception — important for PCOS
The Wegovy prescribing information advises discontinuing semaglutide at least two months before a planned pregnancy because of its long half-life. Weight loss can also restore ovulation in PCOS — meaning pregnancy can happen sooner than expected. Some GLP-1-class medicines can also affect how well oral contraceptives are absorbed. Ask your prescriber which contraception is appropriate while you take one. If you’re trying to conceive, see PCOS and fertility.
Avoid unapproved products
The FDA has warned about unapproved and compounded GLP-1 products, including dosing errors and products of unknown quality. Use only medicines prescribed by a licensed clinician and dispensed by a legitimate pharmacy.
Questions to ask your prescriber
- Is a GLP-1 appropriate for my BMI, metabolic results and goals — or should we start with metformin?
- What contraception should I use while taking it?
- How long before trying to conceive should I stop?
- How will we protect muscle and monitor nutrition?
- What’s the plan if I stop — how do we prevent regain?
Medication works best on top of the foundations. See PCOS weight loss, the PCOS diet and insulin resistance.
Who might be a candidate?
Eligibility depends on the specific product, local prescribing rules and insurance, but broadly GLP-1 receptor agonists for weight management are considered for adults with obesity, or with overweight plus a weight-related health condition. In PCOS, conversations often start when:
- Lifestyle changes have been sustained but weight and metabolic markers haven’t improved enough.
- Prediabetes, raised blood pressure or unfavourable cholesterol are present.
- Pregnancy isn’t planned in the near future, and reliable contraception is in place.
They are generally not appropriate during pregnancy or breastfeeding, and they’re not recommended for people with certain personal or family histories (such as medullary thyroid cancer). Your prescriber will review this.
Eating well on a GLP-1
Appetite can drop sharply, which makes food quality more important, not less:
- Protein first at each meal to help preserve muscle — eggs, yoghurt, fish, poultry, tofu, legumes.
- Smaller, slower meals reduce nausea; stop at the first sign of fullness.
- Fibre and fluids help with constipation, a common side effect.
- Limit high-fat and greasy meals, which often worsen nausea.
- Keep strength training twice a week. See exercise for PCOS.
The 7-day meal plan works well at smaller portions.
Want it all in one calm, organised place?
The PCOS Companion is a 44-page designed guide plus a 32-lesson course — the full picture, sourced and printable. One-time $27, 14-day refund.
Or keep reading — the library is free.
Frequently asked questions
No GLP-1 medicine is approved specifically for PCOS. Wegovy is approved for chronic weight management and Ozempic for type 2 diabetes. In PCOS they’re prescribed for those indications when appropriate.
Research suggests they can lower androgen measures, particularly combined with metformin, and weight loss may improve cycles. Evidence for fertility outcomes is limited.
They serve different roles. Semaglutide produces much more weight loss in trials, while metformin is inexpensive, well established and guideline-recommended for metabolic outcomes. Some people use both. The choice depends on your goals, health, side effects and access.
It’s possible, and weight loss can restore ovulation, so contraception is important. The semaglutide prescribing information advises stopping at least two months before a planned pregnancy.
Many people regain weight after stopping. These medicines are generally considered long-term treatments, and lifestyle foundations help maintain results.
Sources and further reading
- Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi.org/10.1210/clinem/dgad463
- Omarion A, et al. Comparative analysis of GLP-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with PCOS: a network meta-analysis. Front Endocrinol. 2026;17:1833904. doi.org/10.3389/fendo.2026.1833904
- Lin J, et al. The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis. J Ovarian Res. 2026;19(1). doi.org/10.1186/s13048-026-02078-x
- Jobanputra R, et al. The effects of GLP-1 receptor agonists and SGLT2 inhibitors on lean body mass in humans: a systematic review and meta-analysis of randomised controlled trials. Diabetes Metab Res Rev. 2026;42(5):e70194. doi.org/10.1002/dmrr.70194
- U.S. Food and Drug Administration. WEGOVY (semaglutide) injection — prescribing information (2021). www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Morley LC, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with PCOS, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017;11:CD003053. doi.org/10.1002/14651858.CD003053.pub6
Medical disclaimer: this article is educational and is not medical advice. It can’t diagnose or treat any condition. Talk to your clinician before changing medication, supplements, diet or exercise. Read our full disclaimer.